Carglumic acid is an orphan drug, marketed by Orphan Europe under the trade name Carbaglu. Carglumic acid is used for the treatment of hyperammonaemia in patients with N-acetylglutamate synthase deficiency. The initial daily dose ranges from 100 to 250 mg/kg, adjusted thereafter to maintain normal plasma levels of ammonia. References: Matoori S, Leroux JC. Recent advances in the treatment of hyperammonemia. Adv Drug Deliv Rev. 2015 Aug 1;90:55-68. doi: 10.1016/j.addr.2015.04.009. Epub 2015 Apr 17. Review. PubMed PMID: 25895618.

纯度：≥98%

CAS：1188-38-1